

Summary

We seek a risk investor to provide 70,000 euro working capital to push our revolutionary light therapy through its early growth phase. This phase is scoped to the documentation of 70 patients over the next six months. This is sufficient to build early win dossiers for the insurance companies to assess.

The Problem

Continuous improvement creates value in every field, except in medicine where it is forbidden. Exceptional circumstances forced us to use it.

Today the public does not recognise that the doctors prevent continuous improvement. Certainly not that it the very thing that would deliver value for money. Although the medical market regulator is aware of the problem, there are entrenched interests that prevent adoption. In 2012 the FDA of the USA created the 'breakthrough therapy designation' for serious or life threatening conditions. Today, this is the most advanced regulation, close to adopting continuous improvement. Under this designation our therapy could be approved on preliminary evidence.

However, even under this most advanced regulation, it would take five years to gather the required preliminary evidence and to obtain approval. In those five years, technical advances would render our prototype light therapy obsolete. Imagine the result if Apple applied a similar approval process to mobile telephones.

Early Wins

We will make the regulator adopt continuous improvement. We will do this by making the public aware of their missed opportunity. We believe that the best way to make the public aware is by persuading the insurance companies to reimburse for them. This requires case dossiers.

Our light therapy uses commodity components and transforms the cost structure of cancer treatment. Healthcare insurance companies in the EU already reimburse light therapy but not yet for cancer. We believe health insurance companies will reimburse line extensions because they dramatically reduce costs.

The focus of the early growth phase is to create the case dossiers needed to propose our light therapy to health insurance companies. We have closed off our proof of concept and showed that we can make cancer melt like snow under the sun. Our prototype light therapy is already able to create early wins for indications where the current light source penetrates well. This is a very long list of cancers that include high incidence tumours such as breast and prostate.

Even during the early growth period, we are committed to improve our light therapy to create ever more value. Improvements are made monthly. In the coming six months we expect to be able to treat the even the most aggressive forms of pancreatic and brain cancer.

Building Early Win Dossiers

The assessment dossiers to be proposed to insurance companies will contain:

- Case data on efficacy: A scan before and after treatment
- Case data on safety: photo documenting, fever & oedema measurements, patients subjective input
- Case Rationale: input for continuous improvement of the cure rate and eliminate side effects

Budget

Our team is self-investing time and effort. So far only our medical expert has accepted a little remuneration. Patient payments cover the cost of medicines that are expensive to manufacture at today's low volume. These medicines will become very affordable at high volumes. Our engineers will continue to self-invest.

The documentation of the 70 cases and building assessment reports creates additional workload and expense that cannot be supported through self-investing. Direct expenses are estimated at 500 euro per case. The Huppel/Chapman management team require an incremental income of 3000/1500 euro per month respectively. There will be administrative costs for TP4C of around 8000 euro.

A €70,000 budget is required.